Statins for Prevention of Contrast Induced Nephropathy

Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease

In this randomized study the investigators wish to explore the role of pre-procedural statin therapy for the prevention of contrast induced nephropathy in patients with moderate-to-severe renal dysfunction, submitted to elective coronary or angioplasty.

Inclusion Criteria:

• patients with pre-angiographic estimated creatinine clearance < 60 ml/min

Exclusion Criteria:

• contrast medium administration within the previous 10 days
• end-stage renal failure requiring dialysis
• refusal to give informed consent
• previous therapy with statin